There are numerous genetic events in pancreatic cancer that could potentially lead to activation of AKT, including mutations of either K-ras or PTEN, and constitutive activation of a variety of receptor tyrosine kinases. This evidence concerns the gene NTRK1 and familial pancreatic carcinoma.